Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML	Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome	Recruiting	Phase 1 / Phase 2	2026-09-16		NCT05807932

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Heinrich-Heine University, Duesseldorf	71
Koordinierungszentrum für Klinische Studien - Duesseldorf	1

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Klinikum rechts der Isar der TU München Klinik und Poliklinik für Innere Medizin III	München	Germany	1
Universitätsklinikum Aachen - Med. Klinik IV	Aachen	Germany	1
Universitätsklinikum Düsseldorf - Klinik für Hämatologie, Onkologie und Klinische Immunologie	Düsseldorf	Germany	2
Universitätsklinikum Frankfurt Medizinische Klinik II	Frankfurt	Germany	1
Universitätsklinikum Jena - Klinik für Innere Medizin II	Jena	Germany	1
Universitätsklinikum Köln Klinik I für Innere Medizin	Cologne	Germany	1